AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9851729 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapies in patients with DM
Number of subjects: 0
Study 9851729 — intervention group
Group type: COMPARATOR
Intervention: Uncontrolled trials in PM
Number of subjects: 0
Study 10393600 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer
Number of subjects: 17
Study 10393600 — intervention group
Group type: COMPARATOR
Intervention: pMDI with holding chamber
Number of subjects: 17
Study 2050832 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HC) 72 +/- 26 mg/d
Number of subjects: 22
Study 2050832 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (SP) 144 +/- 53 mg/d
Number of subjects: 22
Study 2050832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 6846677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group treatment procedures
Number of subjects: 93
Study 6846677 — intervention group
Group type: COMPARATOR
Intervention: Individual counseling
Number of subjects: 93
Study 30001258 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose folic acid (5 mg/wk)
Number of subjects: 40
Study 30001258 — intervention group
Group type: COMPARATOR
Intervention: Low-dose folic acid (0.8 mg/wk)
Number of subjects: 40
Study 29482433 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengvaxia (tetravalent live-attenuated 3-dose vaccine composed of chimeras of yellow fever 17D and the four dengue viruses)
Number of subjects: 35000
Study 24998405 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management without physical therapy
Number of subjects: 30
Study 24998405 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ankle sprains
Number of subjects: 30
Study 24998405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 30
Study 24998405 — intervention group
Group type: EXPERIMENTAL
Intervention: Deficits in muscle strength of dorsiflexors
Number of subjects: 30
Study 23758981 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression surgery with application of PRP
Number of subjects: 0
Study 23758981 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic subacromial decompression surgery
Number of subjects: 0
Study 21623342 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand-only PCEA (0.125% levobupivacaine plus 1.5 mcg/mL fentanyl, 10 mL bolus with a 20 min lock time)
Number of subjects: 40
Study 21623342 — intervention group
Group type: COMPARATOR
Intervention: PCEA plus background infusion (10 mL/h)
Number of subjects: 40
Study 19874650 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mg/kg oral MDMA
Number of subjects: 16
Study 19874650 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg oral MDMA
Number of subjects: 16
Study 19874650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17032096 — intervention group
Group type: EXPERIMENTAL
Intervention: Forgiveness Therapy (FT)
Number of subjects: 20
Study 17032096 — intervention group
Group type: COMPARATOR
Intervention: Alternative Treatment (AT)
Number of subjects: 20
Study 15068419 — intervention group
Group type: EXPERIMENTAL
Intervention: L. brevis (CD2)
Number of subjects: 22
Study 15068419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10647315 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA (6 mg/kg intravenous infusion)
Number of subjects: 16
Study 10647315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8618603 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1000 mg three times daily)
Number of subjects: 725
Study 8618603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 725
Study 1610712 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% crude coal tar used twice daily for 10 days
Number of subjects: 20
Study 1610712 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental regimen starting at 5% and increasing by 5% every second day to a maximum of 25%
Number of subjects: 20
Study 1610712 — intervention group
Group type: COMPARATOR
Intervention: 5% crude coal tar
Number of subjects: 20
Study 1610712 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental regimen starting at 5%
Number of subjects: 20
Study 6705284 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prenalterol at doses of 20, 40, 100, and 200 mg daily for four weeks
Number of subjects: 10
Study 6705284 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prenalterol
Number of subjects: 10
Study 30642068 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) from burn patients
Number of subjects: 0
Study 30642068 — intervention group
Group type: COMPARATOR
Intervention: Platelet-rich plasma (PRP) from healthy volunteers
Number of subjects: 0
Study 30642068 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet count of PRP
Number of subjects: 0
Study 30016948 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Task Exercise (FTE)
Number of subjects: 155
Study 30016948 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive Physical Therapy (PPT)
Number of subjects: 155
Study 30016948 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Usual Care)
Number of subjects: 155
Study 30016948 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between FTE and PPT
Number of subjects: 155
Study 26708510 — intervention group
Group type: EXPERIMENTAL
Intervention: Preadmission application of chlorhexidine gluconate, 2% with electronic alert (EA)
Number of subjects: 100
Study 26708510 — intervention group
Group type: COMPARATOR
Intervention: Preadmission application of chlorhexidine gluconate, 2% without electronic alert (no-EA)
Number of subjects: 100
Study 26708510 — intervention group
Group type: EXPERIMENTAL
Intervention: Preadmission application of chlorhexidine gluconate, 2%
Number of subjects: 100
Study 24528690 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3‐FFA 2 g/d
Number of subjects: 399
Study 24528690 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3‐FFA 3 g/d
Number of subjects: 399
Study 24528690 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3‐FFA 4 g/d
Number of subjects: 399
Study 24528690 — intervention group
Group type: COMPARATOR
Intervention: Control (olive oil [OO] 4 g/d)
Number of subjects: 399
Study 23171601 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry intervention (cognitive-behavioral treatment)
Number of subjects: 150
Study 23171601 — intervention group
Group type: COMPARATOR
Intervention: Standard care (treatment as usual)
Number of subjects: 150
Study 20018249 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 48
Study 20018249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 18274167 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-deficiency anemia
Number of subjects: 337
Study 16286622 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intervention (comprehensive vision restoration‐rehabilitation program including assistance in obtaining cataract surgery)
Number of subjects: 28
Study 16286622 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 28
Study 12011946 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol combined with total sleep deprivation
Number of subjects: 10
Study 12011946 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with total sleep deprivation
Number of subjects: 10
Study 10207545 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) monotherapy
Number of subjects: 1280
Study 10207545 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) plus didanosine (ddI)
Number of subjects: 1280
Study 10207545 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) plus zalcitabine (ddC)
Number of subjects: 1280
Study 10207545 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) monotherapy and combination arms
Number of subjects: 1280
Study 10207545 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV RNA nadirs achieved
Number of subjects: 1280
Study 10207545 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HIV RNA levels adjusted for CD4 cell counts
Number of subjects: 1280
Study 10207545 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum HIV RNA achieved in the first 16 weeks
Number of subjects: 1280
Study 10207545 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 cell counts
Number of subjects: 1280
Study 10445104 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropins (GN) alone for 6 months
Number of subjects: 4
Study 10445104 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropins (GN) combined with growth hormone (GH) for 6 months
Number of subjects: 4
Study 2142930 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestodene-containing formulation
Number of subjects: 18
Study 2142930 — intervention group
Group type: COMPARATOR
Intervention: Desogestrel-containing formulation
Number of subjects: 18
Study 902005 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling on medication errors
Number of subjects: 165
Study 902005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear-off daily calendar
Number of subjects: 165
Study 902005 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill wheel
Number of subjects: 165
Study 902005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet identification card
Number of subjects: 165
Study 30862265 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) for transferred patients
Number of subjects: 1526
Study 28505332 — intervention group
Group type: EXPERIMENTAL
Intervention: DMF-exposed workers
Number of subjects: 886
Study 28505332 — intervention group
Group type: EXPERIMENTAL
Intervention: Male DMF-exposed workers
Number of subjects: 886
Study 28505332 — intervention group
Group type: EXPERIMENTAL
Intervention: NMF
Number of subjects: 886
Study 28505332 — intervention group
Group type: EXPERIMENTAL
Intervention: AMCC
Number of subjects: 886
Study 28505332 — intervention group
Group type: EXPERIMENTAL
Intervention: NMHb
Number of subjects: 886
Study 26458813 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-zirconium (TiZr) implants
Number of subjects: 47
Study 26458813 — intervention group
Group type: COMPARATOR
Intervention: Titanium Grade IV (Ti Grade IV) implants
Number of subjects: 47
Study 23992793 — intervention group
Group type: EXPERIMENTAL
Intervention: General therapy skills (feedback and understanding)
Number of subjects: 79
Study 23992793 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical skill of guided discovery
Number of subjects: 79
Study 21574351 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted therapy (V.A.C. Therapy system)
Number of subjects: 43
Study 21574351 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (including debridement)
Number of subjects: 43
Study 19121493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting on the base of brackets (Group 1)
Number of subjects: 80
Study 19121493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting + silane-coupling agent (Group 2)
Number of subjects: 80
Study 19121493 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribochemical treatment (Group 3)
Number of subjects: 80
Study 19121493 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconditioned with sandblasting (Group 5)
Number of subjects: 80
Study 19121493 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 4)
Number of subjects: 80
Study 16713778 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (7 mg)
Number of subjects: 110
Study 16713778 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (20 mg)
Number of subjects: 110
Study 16713778 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 110
Study 16713778 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 110
Study 16713778 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine for failed etomidate intubation
Number of subjects: 110
Study 16713778 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepine for failed midazolam intubation
Number of subjects: 110
Study 15514879 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral Condensation (LC)
Number of subjects: 79
Study 15514879 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Condensation (HC)
Number of subjects: 79
Study 11312014 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent dengue vaccines (dengue-1, dengue-2, dengue-3, dengue-4)
Number of subjects: 40
Study 11312014 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine
Number of subjects: 40
Study 11312014 — intervention group
Group type: COMPARATOR
Intervention: Vaccine vehicle (control)
Number of subjects: 40
Study 11312014 — intervention group
Group type: EXPERIMENTAL
Intervention: All dengue-3, dengue-4, and tetravalent vaccine recipients
Number of subjects: 40
Study 11312014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue-1 and dengue-2 vaccine recipients
Number of subjects: 40
Study 11312014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue-2, dengue-3, dengue-4, and 60% of dengue-1 vaccine recipients
Number of subjects: 40
Study 11312014 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent vaccine recipients
Number of subjects: 40
Study 11312014 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven volunteers
Number of subjects: 40
Study 9250115 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat-bran test meal (16.3 g fiber)
Number of subjects: 6
Study 9250115 — intervention group
Group type: COMPARATOR
Intervention: Wheat test meal (6.3 g fiber)
Number of subjects: 6
Study 7945494 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (0.5 mg/kg of prednisone daily)
Number of subjects: 10
Study 7945494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3652280 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin alone
Number of subjects: 0
Study 3652280 — intervention group
Group type: COMPARATOR
Intervention: Azlocillin plus amikacin
Number of subjects: 0
Study 31972396 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein biomarker signature for early detection of CRC derived from 270 protein markers measured in plasma samples.
Number of subjects: 100
Study 31972396 — intervention group
Group type: COMPARATOR
Intervention: External validation of the protein biomarker signature in a representative screening population.
Number of subjects: 100
Study 31972396 — intervention group
Group type: COMPARATOR
Intervention: Three-marker early-stage algorithm for detection of AA.
Number of subjects: 100
Study 30061275 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 60
Study 30061275 — intervention group
Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3DCRT)
Number of subjects: 60
Study 27181755 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Diabetes Manual + Diabetes Treatment Guide + 30-min seminar
Number of subjects: 416
Study 27181755 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Treatment Guide only
Number of subjects: 416
Study 25916420 — intervention group
Group type: EXPERIMENTAL
Intervention: Audible music group (MG)
Number of subjects: 33
Study 25916420 — intervention group
Group type: COMPARATOR
Intervention: Mute music group (CG)
Number of subjects: 33
Study 22246660 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated multi-behavior intervention
Number of subjects: 337
Study 22246660 — intervention group
Group type: COMPARATOR
Intervention: Education-only control
Number of subjects: 337
Study 20537615 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naltrexone (50 mg daily)
Number of subjects: 69
Study 20537615 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant naltrexone (2.3 g single dose)
Number of subjects: 69
Study 20537615 — intervention group
Group type: COMPARATOR
Intervention: Blood naltrexone concentration < 0.5 ng/mL
Number of subjects: 69
Study 20537615 — intervention group
Group type: COMPARATOR
Intervention: Blood naltrexone concentration 3 ng/mL
Number of subjects: 69
Study 20537615 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant naltrexone
Number of subjects: 69
Study 20537615 — intervention group
Group type: COMPARATOR
Intervention: Oral naltrexone
Number of subjects: 69
Study 20537615 — intervention group
Group type: COMPARATOR
Intervention: Lower craving scores (<= 20/70)
Number of subjects: 69
Study 20537615 — intervention group
Group type: COMPARATOR
Intervention: Noncompliance with daily oral formula, higher baseline craving, longer history of use, being younger
Number of subjects: 69
Study 18672743 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture (n = 23), administered once daily for the first three days and once every three days for the remaining 11 days, plus placebo pill once daily
Number of subjects: 44
Study 15939389 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy surgery
Number of subjects: 300
Study 12617044 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic operation using the overlap technique and intraperitoneal mesh
Number of subjects: 0
Study 12617044 — intervention group
Group type: COMPARATOR
Intervention: Open technique with overlap
Number of subjects: 0
Study 12617044 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh repair for larger hernias
Number of subjects: 0
Study 12617044 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free technique
Number of subjects: 0
Study 12617044 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap technique
Number of subjects: 0
Study 10352763 — intervention group
Group type: EXPERIMENTAL
Intervention: Biceps load test
Number of subjects: 75
Study 7482644 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke rehabilitation unit (n = 34)
Number of subjects: 71
Study 7482644 — intervention group
Group type: COMPARATOR
Intervention: General wards (n = 37)
Number of subjects: 71
Study 1781820 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 1.5 mg/kg/d
Number of subjects: 33
Study 1781820 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 0.75 mg/kg/d
Number of subjects: 33
Study 1781820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 1781820 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 33
Study 121456 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) ointment
Number of subjects: 17
Study 121456 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 17
Study 31960773 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dry needling with needle manipulation
Number of subjects: 42
Study 31960773 — intervention group
Group type: COMPARATOR
Intervention: Deep dry needling without needle manipulation
Number of subjects: 42
Study 30877596 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 63
Study 30877596 — intervention group
Group type: COMPARATOR
Intervention: Support group
Number of subjects: 63
Study 28129492 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (25-200 mg/d for 12 weeks)
Number of subjects: 10
Study 26239090 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose UFH (100 U/kg bolus followed by age-based continuous infusion)
Number of subjects: 149
Study 26239090 — intervention group
Group type: COMPARATOR
Intervention: Low-dose UFH (50 U/kg bolus)
Number of subjects: 149
Study 26239090 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH dose and effect
Number of subjects: 149
Study 26239090 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Xa, aPTT, ACT assays
Number of subjects: 149
Study 23390076 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 61
Study 23390076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 21081593 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation (PPV) delivered with a T‐piece or self‐inflating bag and a round silicone face mask.
Number of subjects: 56
Study 19329177 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg
Number of subjects: 15548
Study 19329177 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15548
Study 16311083 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of octreotide and methylglucamine diatrizoate
Number of subjects: 162
Study 16311083 — intervention group
Group type: COMPARATOR
Intervention: Control group (treated conservatively)
Number of subjects: 162
Study 15344622 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray MTA
Number of subjects: 24
Study 15344622 — intervention group
Group type: EXPERIMENTAL
Intervention: White MTA
Number of subjects: 24
Study 15344622 — intervention group
Group type: EXPERIMENTAL
Intervention: Formocresol
Number of subjects: 24
Study 11757832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin + rifampicin (50 mg/L each)
Number of subjects: 98
Study 11757832 — intervention group
Group type: COMPARATOR
Intervention: Cephradine (250 mg/L)
Number of subjects: 98
Study 9048273 — intervention group
Group type: EXPERIMENTAL
Intervention: Fantofarone 100 mg twice daily
Number of subjects: 330
Study 9048273 — intervention group
Group type: EXPERIMENTAL
Intervention: Fantofarone 150 mg twice daily
Number of subjects: 330
Study 9048273 — intervention group
Group type: EXPERIMENTAL
Intervention: Fantofarone (100-150 mg twice daily)
Number of subjects: 330
Study 9048273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 9048273 — intervention group
Group type: EXPERIMENTAL
Intervention: Fantofarone (all doses)
Number of subjects: 330
Study 8151104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 10
Study 8151104 — intervention group
Group type: COMPARATOR
Intervention: 5 g of OA
Number of subjects: 10
Study 8151104 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of OA
Number of subjects: 10
Study 8151104 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g of OA
Number of subjects: 10
Study 3529043 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton/polyester covergowns worn over scrubsuits during lunch period outside the OR
Number of subjects: 0
Study 3529043 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh scrubsuits put on following the lunch period
Number of subjects: 0
Study 3529043 — intervention group
Group type: COMPARATOR
Intervention: Scrubsuits worn unprotected outside the OR during lunch
Number of subjects: 0